Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Phillips Carbon Black Limited - Updates

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Updates

2018-06-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

22
Closing Bell: Banks, oil, infra stocks drag Sensex 273 pts; Nifty ends below 10,700 ahead of FO expiry

2018-06-27 moneycontrol
On the global front, Asian markets closed lower, led by the drop in Chinese stocks amid lingering trade worries. China's Shanghai Composite was down 1.11 percent and Hong Kong's Hang Seng shed 1.82 percent while Japan's Nikkei lost 0.3 percent.
JUBILANT 500325 JIPKY 533096 MGHOF HCTHY 530019 532712 512599 SYNDIBANK RCOM 506590 532281 PHILIPCARB BJJQY RLNIY ANNRY 532947 JETAIRWAYS IRB 532865 532622 JSWSTEEL BAJAJFINSV 532276 BAJFINANCE HCLTECH HCCC 532939 ADANIENT 500228 RELIANCE IDBI 532617 532978 IBRQY RIGD 500034 RPOWER 500116 IBN JPASSOCIAT 539207 532532 M30 ICICIBANK GDL 532174 ADANIPOWER MANPASAND MEGH

0
Phillips Carbon Black Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Shareholders meeting

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Book Closure

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
Phillips Carbon Black Limited - Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

0
PCBL to set up plant in Tamil Nadu for Rs 600 crore

2018-05-04 moneycontrol
Phillips Carbon Black Ltd (PCBL) will set up a greenfield carbon black plant in Tamil Nadu and undertake brownfield expansion in two of the existing plants at a combined capex of Rs 900 crore over the next two years, a top official of the company today claimed.
506590 PHILIPCARB

24
Market Live: Sensex falls 250 pts, Nifty breaks 10,600; rupee extends losses

2018-05-04 moneycontrol
Earnings: Ambuja Cements has reported standalone profit at Rs 271.8 crore for the quarter ended March 2018, a growth of 10.3 percent over Rs 246.5 crore reported in year-ago.
BAJAJ-AUTO 500325 500820 500425 533150 RELIANCE ATB 532977 HDFC BHRQY AMBUJACEM ASIANPAINT 532215 532541 AMBUY AXISBANK 506590 RIGD PHILIPCARB 500412 BHARTIARTL 500010 RLNIY NIITTECH YESBANK HINDALCO CARBORUNIV AXB 532648 YYBKY 513375 AXBKY TIRUMALCHM HNDNF 532454 AXBA GODREJPROP 534809 PCJEWELLER HDFC 500440

0
Phillips Carbon Black Limited - Financial Result Updates

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506590 PHILIPCARB

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...